Obsidian Therapeutics merges with Galera
RTW Biotech Opportunities said Obsidian Therapeutics completed its merger with Galera Therapeutics Inc. via a reverse merger, with a concurrent private financing of about $350m. The combined company began trading on Nasdaq as Obsidian Therapeutics under ticker OBX on 4 Aug 2026. Proceeds are expected to fund operations into H2 2028.
How this was made
The 30-second read
Why it matters
The key tradable development is the new Nasdaq listing for the combined company (OBX) and the stated intent to fund operations into 2H 2028, which can shift expectations for capital needs and near-term survival risk.
Market read
A completed reverse merger plus ~$350m financing creates a fresh, tradable biotech listing (OBX) with a stated funding horizon into 2H 2028.
What to watch
No details are provided here on trial readouts, cash burn rate, or dilution terms of the ~$350m financing, which can materially change valuation and near-term trading behavior.
Background
RTW Biotech Opportunities (LSE: RTW) reports the completion of Obsidian Therapeutics’ reverse merger with Galera and the concurrent private financing.
Ticker impact
Obsidian Therapeutics began trading on Nasdaq under ticker OBX on 4 Aug 2026 after completing its reverse merger with Galera and a ~$350m financing.
Likely positive near-term bias as traders price the new listing and capital overhang, but volatility is elevated given clinical-stage risk.
The article discloses a completed merger, a new Nasdaq trading ticker, and a stated financing size and intended funding horizon, which are actionable for positioning around the first trading days.
Market effects
Highlights continued use of reverse mergers to bring clinical-stage cell-therapy platforms to public markets with sizable financings.
Limited direct macro impact; primarily affects US biotech trading flows and LSE-listed RTW Bio sentiment.
Moderate, as it reflects ongoing global capital formation for oncology cell therapies.
Counterpoint
The disclosed funding runway may not eliminate dilution or clinical binary risk, so the initial listing pop could fade quickly.
Key entities
- companyObsidian Therapeutics
Clinical-stage biopharmaceutical developing cell therapies using protein-regulation technology; lead candidate OBX-115 in Phase 2 (melanoma) and Phase 1 (NSCLC).
- companyGalera Therapeutics Inc.
Public company that merged with Obsidian; combined company trades on Nasdaq under OBX after the reverse merger.
- companyRTW Biotech Opportunities Ltd
LSE-listed investment company that invested in Obsidian and reports MOIC and NAV uplift tied to the new public listing.
